Evidence map›Paper›PMID 30457249›Full record

ArticleActa clinica Croatica2018

Expression of LMO2 in Prostate Carcinoma and Adjacent Prostatic Parenchyma.

Božo Krušlin, Majda Vučić, Silvija Mašić, Ivan Kruljac, Cvjetko Lež, Boris Ružić, Borislav Spajić, Monika Ulamec

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta clinica Croatica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Božo KrušlinLjudevit Jurak Department of Pathology and Cytology, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia.
Majda VučićLjudevit Jurak Department of Pathology and Cytology, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia.
Silvija MašićLjudevit Jurak Department of Pathology and Cytology, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia.
Ivan KruljacMladen Sekso Department of Endocrinology, Diabetes and Metabolic Diseases, Vinogradska cesta 29, Zagreb, Croatia.
Cvjetko LežDepartment of Pathology and Cytology, Zabok General Hospital, Bračak, Croatia.
Boris RužićDepartment of Pathology, School of Medicine, University of Zagreb, Zagreb, Croatia.
Borislav SpajićDepartment of Pathology, School of Medicine, University of Zagreb, Zagreb, Croatia.
Monika UlamecLjudevit Jurak Department of Pathology and Cytology, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia.
University Hospital Centre Zagreb · HRUniversity of Zagreb · HRUniversity of Osijek · HR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

LMO2 (LIM domain only) is a member of transcription factor family of proteins characterized by their cysteine-rich, zinc-binding LIM domains. Its expression in prostate cancer cells, as well as in adjacent stroma, is described in a study in a cohort of 83 patients treated with radical prostatectomy for clinically localized prostate adenocarcinoma. Authors found that LMO2 overexpression in prostate cancer was strongly associated with features indicative of worse prognosis (higher preoperative PSA, higher Gleason score, positive surgical margins, and extraprostatic extension of disease). Expression of LMO2 was also associated with biochemical disease progression. We analysed immunohistochemical expression of LMO2 in prostate cancer epithelial and stromal cells, as well as in adjacent parenchyma. Significant negative correlation between glandular expression of LMO2 in carcinoma and stromal expression in BPH (ρ = -0.238, P = 0.033) was found, but also be-tween stromal expression in carcinomas and glandular expression in BPH (ρ = -0.255, P = 0.021). Positive correlation was found between stromal expression in BPH and stromal expression in carci-nomas (ρ = 0.306, P = 0.005). Study results support the potential role of LMO2 in prostatic carcino-genesis and cancer progression.

Indexed as

Adaptor Proteins, Signal TransducingLIM Domain ProteinsProstatectomyProstatic NeoplasmsProto-Oncogene ProteinsDisease ProgressionHumansMalePrognosisProstate-Specific AntigenAdaptor Proteins, Signal TransducingLIM Domain ProteinsLMO2 protein, humanProstate-Specific AntigenProto-Oncogene ProteinsLMO2Prostate cancerStromal reaction

Identifiers

PMID30457249
PMCPMC12231090
OpenAlexW3010881558

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.